Literature DB >> 1085678

Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.

J S Cameron, M H Lessof, C S Ogg, B D Williams, D G Williams.   

Abstract

Serum C4 and C3 concentration and binding of double-stranded-DNA (ds-DNA) were measured in sera from ninety-nine patients with systemic lupus erythematosus and clinical evidence of nephritis. C3 and C4 concentrations correlated poorly with ds-DNA binding. In sera from fifty-three patients, precipitating antibody was sought using the counterimmunoelectrophoretic technique. Precipitating antibody was detected on at least one occasion in 44% of the patients, and these sera with precipitating antibody showed higher binding of ds-DNA and lower C4 concentrations than those without precipitating antibody. In thirty-two patients, serial assessments of the activity of the renal disease were made using decline or improvement in glomerular filtration rate, degree of proteinuria, oedema and hypertension as indices of "activity". All patients were receiving immunosuppressive drugs. Active nephritis was rarely found in patients showing, at that time, a normal serum C4 or normal ds-DNA binding; but a raised ds-DNA binding or lowered serum C4 were found in both active and inactive nephritis. There was no correlation of activity with serum concentrations of C3, or the presence or absence of precipitating antibody. We conclude that measurements of serum-complement concentrations and binding of ds-DNA are of most use in the diagnosis of systemic lupus erythematosus, and that in patients with nephritis and taking immunosuppressive drugs, these tests are of limited use in guiding treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1085678      PMCID: PMC1541413     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations.

Authors:  A Cruchaud; F Chenais; G J Fournié; L Humair; P H Lambert; J C Mulli; F Chatelanat
Journal:  Eur J Clin Invest       Date:  1975-06-12       Impact factor: 4.686

2.  Precipitating antibody to D.N.A. detected by two-stage electroimmunodiffusion. Study in S.L.E. and in rheumatoid arthritis.

Authors:  G D Johnson; J P Edmonds; E J Holborow
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

3.  Cyclophosphamide in lupus nephritis: a controlled trial.

Authors:  A D Steinberg; H B Kaltreider; P J Staples; E J Goetzl; N Talal; J L Decker
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

4.  Azathioprine in the treatment of systemic lupus erythematosus. A controlled study.

Authors:  M Sztejnbok; A Stewart; H Diamond; D Kaplan
Journal:  Arthritis Rheum       Date:  1971 Sep-Oct

5.  Character of anti-DNA antibodies in systemic lupus erythematosus.

Authors:  S A Cohen; G R Hughes; G L Noel; C L Christian
Journal:  Clin Exp Immunol       Date:  1971-04       Impact factor: 4.330

6.  Experimental chronic glomerulitis.

Authors:  T Pincus; R Haberkern; C L Christian
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

7.  Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid.

Authors:  R T Wold; F E Young; E M Tan; R S Farr
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

8.  Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months.

Authors:  J L Decker; J H Klippel; P H Plotz; A D Steinberg
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

9.  The range and specificity of antinuclear antibodies in systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; E Fishbein; H Alcalá; E Olguín-Palacios; S Estrada-Parra
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

10.  Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei.

Authors:  T Tojo; G J Friou
Journal:  Science       Date:  1968-08-30       Impact factor: 47.728

View more
  19 in total

Review 1.  Role of circulating soluble immune complexes in disease.

Authors:  R J Levinsky
Journal:  Arch Dis Child       Date:  1978-02       Impact factor: 3.791

2.  Lupus nephritis. Middlesex, October 20, 1988. Abstracts.

Authors: 
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

3.  The treatment of lupus nephritis by methyl prednisolone pulse therapy.

Authors:  S Dosa; S A Cairns; W Lawler; N P Mallick; I N Slotki
Journal:  Postgrad Med J       Date:  1978-09       Impact factor: 2.401

4.  The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations.

Authors:  S A Cairns; A London; N P Mallick
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

Review 5.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.

Authors:  S A Cairns; E J Acheson; C L Corbett; S Dosa; N P Mallick; W Lawler; G Williams
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

7.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  DNA-anti-DNA circulating complexes in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; J Dobson; D G Williams
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

Review 9.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

10.  Studies on autoantibodies to poly (adenosine diphosphate-ribose) in SLE and other autoimmune diseases.

Authors:  W J Morrow; D A Isenberg; H F Parry; L Shen; E E Okolie; F Farzaneh; S Shall; M L Snaith
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.